Clinical Trial Update: Regorafenib After Failure of Lenvatinib in Patients With Unresectable HCC: The RELEVANT-HCC Trial [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating regorafenib for unresectable hepatocellular carcinoma after lenvatinib failure (RELEVANT-HCC); the study is not yet recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• LENVIMA (lenvatinib)
• Stivarga (regorafenib)

Snippet

Sponsor: Ju Hyun Shim | Conditions: Carcinoma, Hepatocellular, Lenvatinib | Phase 2 | Status: NOT_YET_RECRUITING